Traditional methods for target discovery rely on preclinical models and phenotypic screens that frequently fail to predict clinical efficacy. The availability of human genetic data has surged in recent years, enabling the discovery of novel high-confidence targets. Currently, however, discovery efforts are limited by the inability to accurately predict the functional consequences (e.g. loss-of-function, neutral, gain-of-function) of genetic variants in human populations.
The Genable Platform
Genable™ is a cutting-edge platform designed to address current limitations in genomics-based target identification & prioritization through the use of massively-multiplexed experiments, human data, and machine learning. The platform uses a proprietary, integrated experimental and computational approach to confidently determine functional consequences of genetic variants observed in the population, ensuring that only the most promising targets are advanced. Genable thus provides a significant advantage over conventional target identification methods.
Enhanced association analysis
Increased Success Rates
Genable harnesses the 4x increased success rate of genetically-supported targets, increasing the chance of approval.
Accelerated Discovery
Accelerates drug target discovery, validation, and prioritization through direct functional validation of impact on disease biology.
Decreased development costs
By advancing only targets of the highest confidence, Genable reduces sunk costs associated with failed drug candidates.
